[1] |
Lloyd I.Pharma R&D Annual Review 2020[EB/OL].(2020-07-18)[2021-09-12]. https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2020/files/whitepapers/rd-review-2020-whitepaper-update.pdf.
|
[2] |
Li R, Meng J, Zhao RC, et al. Analysis of research and development status of new drugs in 2022[J]. Chin Bull Life Sci (生命科学), 2023, 35(1): 80-87.
|
[3] |
Frost & Sullivan. China CRO Industry Market Research Report.[EB/OL][2020-06-19].https://www.frostchina.com/content/insight/detail?id=62f366d357d0761f000a3433.
|
[4] |
BDO. Revenue, R&D and biotech''s future[EB/OL]. [2021-12-20]. https://www.bdo.com/BDO/media/Misc-Documents/LS_Biotech-Brief-Report_Summer-2021_WEB.pdf.
|
[5] |
Deloitte. Seeds of change: measuring the return from pharmaceutical innovation 2020[EB/OL]. (2021-07-20)[2021-12-20]. https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-care /deloitte-uk-measuring-the-return-from-pharmaceutical-innovation-2021.pdf.
|
[6] |
Chen J, Dong Z. Influence and countermeasures and suggestions of medical outsourcing in China on the basis of drug registration system reform[J]. China Pharm (中国药业), 2018, 27(23): 70-73.
|
[7] |
Wu X, Shao R. Current situation and analysis of venture capital of innovative medicine[J]. Chin J Pharm (中国医药工业杂志), 2020, 51(8): 1070-1079.
|
[8] |
Fu P, Lu JJ, Sun SY. Discussion on prospect of pharmaceutical innovation market and development of CRO industry in 2020[J]. Tianjin Sci Technol (天津科技), 2020, 47(5): 94-96.
|
[9] |
Yao W, Yan JZ, Shao R. A study on the evaluation criteria of medical insurance negotiation admittance for innovative drugs in typical countries and its enlightenment to China[J]. Chin J New Drugs (中国新药杂志), 2021, 30(12): 1057-1062.
|
[10] |
Yin SQ, Zhang H, Liu YH. The effect of policy implementation and some relevant suggestions on the inclusion of innovative tumor drugs in the national reimbursement drug list[J]. Chin Health Econ (中国卫生经济), 2021, 40(1): 22-24.
|
[11] |
IQVIA. Global trends in R&D: overview through 2020[EB/OL]. (2021-05-19)[2021-10-02]. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d.
|
[12] |
China Pharmaceutical Innovation and Research Development Association (PhIRDA), R&D-Based Pharmaceutical Association Committee (RDPAC). Promoting simultaneous R&D, registration and review of innovative drugs, fostering pharmaceutical innovation system in China[J]. China Food Drug Administ Magaz (中国食品药品监管), 2022, 7(222): 4-13.
|
[13] |
Chen H, Chen PX. The hidden worries of "assault R&D"[J].Bus Manage (企业管理), 2020, 5: 48-53.
|
[14] |
Sun TY. China''s pharmaceutical innovation has entered the second tier globally[J].China Econ Week (中国经济周刊), 2022, 5: 62-64.
|